Intravitreal Bevacizumab for Neovascular Glaucoma; a Randomized Placebo Controlled Clinical Trial
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 26
- 试验地点
- 1
- 主要终点
- Change in intraocular pressure
研究概览
简要总结
Several studies have confirmed high levels of vascular endothelial growth factor (VEGF) in eyes with neovascular glaucoma (NVG). The role of VEGF inhibitors in regression of other neovascular disorders such as wet-type age-related macular degeneration and diabetic macular edema has been described. We aim to evaluate the effect of three intravitreal injections of bevacizumab (Avastin) 2.5 mg versus a sham procedure for treatment of NVG. Outcome measures include intraocular pressure and extent of iris neovascularization. Both study arms will receive conventional treatment for NVG.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Outcomes Assessor)
入排标准
- 年龄范围
- 10 Years 至 80 Years(Child, Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Clinical diagnosis of NVG
- •Vision less than 20/200
- •age 10-80 years
排除标准
- •Uncontrolled Blood Pressure
- •History of thromboembolism
- •Congestive Heart Failure
- •Renal Failure
- •Pregnancy or Lactation
- •Active ocular or periocular infection
- •No light perception
研究组 & 干预措施
2
干预措施: subconjunctival normal saline (Other)
1
干预措施: Avastin (Drug)
结局指标
主要结局
Change in intraocular pressure
时间窗: 6 months
Change in extent of iris neovascularization
时间窗: 6 months
次要结局
- Best corrected visual acuity(6 months)
